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Rodent models have been extensively used to investigate the cause and mechanisms
behind Alzheimer’s disease. Despite many years of intensive research using these models
we still lack a detailed understanding of the molecular events that lead to neurodegener-
ation. Although zebraﬁsh lack the complexity of advanced cognitive behaviors evident in
rodent models they have proven to be a very informative model for the study of human
diseases. In this review we give an overview of how the zebraﬁsh has been used to study
Alzheimer’s disease. Zebraﬁsh possess genes orthologous to those mutated in familial
Alzheimer’s disease and research using zebraﬁsh has revealed unique characteristics
of these genes that have been difﬁcult to observe in rodent models. The zebraﬁsh is
becoming an increasingly popular model for the investigation of Alzheimer’s disease and
will complement studies using other models to help complete our understanding of this
disease.
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ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is the most prevalent form of dementia.
It was estimated in 2010 that 36 million people were living with
AD and this ﬁgure is predicted to increase to 66 million by 2030
(World Alzheimer report’s, 2010). The main clinical feature of AD
is progressive memory loss. However, AD can also be character-
ized by the impairment of speech and motor ability, depression,
delusions, hallucinations, and aggressive behavior (Voisin andVel-
las, 2009). Despite these recognizable behavioral differences it is
actually difﬁcult during the early stages of the disease to correctly
diagnose someone as having AD (Blennow et al., 2006). There is
signiﬁcant neuronal loss in several brain regions in AD patients
(Regeur et al., 1994;West et al., 1994). This is usually accompanied
by extracellular aggregates of the amyloid-beta peptide and intra-
cellular aggregates of the tau protein called neuroﬁbrillary tangles
(NFTs).
Alzheimer’s disease can be classed as familial (FAD, usually
with onset <65 years) or sporadic (SAD, onset >65 years). We
have acquired most of our knowledge on the pathogenesis of AD
through studies of FAD mutations. FAD is attributed to muta-
tions in three genes, PRESENILIN 1 (PSEN1), PRESENILIN 2
(PSEN2), and the AMYLOID BETA A4 PRECURSOR PROTEIN
(APP). The PSEN proteins are essential for γ-secretase activity
that cleaves transmembrane domain proteins within lipid bilay-
ers (reviewed in McCarthy et al., 2009). The PSEN proteins and
four other proteins comprise γ-secretase complexes. PSEN (1
or 2), nicastrin (NCT), anterior pharynx defective 1 (APH1a
or APH1b), and presenilin enhancer 2 (PSENEN) form active
γ-secretase complexes in cellular membranes. These complexes
are responsible for the cleavage of a number of single-pass trans-
membrane proteins such as APP and NOTCH. APP is initially
cleaved by α- or β-secretases to release APPα or APPβ fragments,
respectively. The subsequent cleavage of APP by γ-secretase after
β-secretase cleavage liberates amyloid-β (Aβ) peptides of vari-
ous lengths. The longer Aβ-42 peptide is prone to aggregation
and is suggested to form toxic oligomers and ﬁbrils that eventu-
ally deposit as amyloid plaques in the brain. Deposits of plaques
and NFTs are common occurrences in the brains of those with
FAD.
The common, late onset form of AD (accounting for >90%
of cases) occurs sporadically (Blennow et al., 2006). Sporadic
AD (SAD) has a complex etiology and is associated with many
risk factors including old-age and possession of the ε4 allele
of the APOLIPOPROTEIN E (APOE) gene. Human genome
wide association studies have revealed a number of possible
loci associated with risk for SAD [reviewed by Rademakers and
Rovelet-Lecrux, 2009). There are numerous other risk factors
associated with an individual’s lifestyle that can also increase the
likelihood of developing AD. These overlap considerably with
the risk factors for cardiovascular disease (Kotze and van Rens-
burg, 2012) including hypertension, hypercholesterolemia and
obesity (Martins et al., 2006). The molecular and cellular trig-
gers for the onset of SAD are yet to be completely resolved,
however, there have been many hypotheses suggested to explain
how AD is initiated. Of the many hypotheses that have been
postulated over the years, some that are gaining momentum
attribute AD to vasculature dysfunction (Stone, 2008; Marchesi,
2011), oxidative stress (Nunomura et al., 2001), mitochondrial
dysfunction (Selfridge et al., 2012) or hypoxia (Oresic et al.,
2011).
The common observation of amyloid plaques in AD brains
led to the formulation of the amyloid hypothesis in 1992 (Hardy
and Higgins, 1992) that continues to dominate research thinking
as a unifying hypothesis for FAD and SAD. The hypothesis sug-
gests that toxic oligomerization of Aβ peptides is the initiating
factor that triggers a cascade of subsequent cellular abnormalities
such as inﬂammation and oxidative stress (Verdile et al., 2004).
These secondary phenomena ultimately lead to neuronal dys-
function, degeneration and death. Although still widely accepted,
doubts have arisen regarding its validity following several failed
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clinical trials of drugs intended to reduce Aβ levels (refer to
www.alzforum.org regarding information on AD drugs in clinical
trials).
Rodent models of AD have been exploited extensively and have
given considerable insight into this disease. However, we still
do not understand the events that trigger the neurodegeneration
evident in AD. Research using the zebraﬁsh model has revealed
particular characteristics of the various genes implicated in AD
that have been difﬁcult to observe in other animal models (Liao
et al., 2012; Newman et al., 2012). This review will focus on how
the zebraﬁsh has been used to study the genes and various cellular
pathways implicated in FAD and SAD pathogenesis and will con-
clude by examining the limitations of the zebraﬁsh and what the
future may hold for use of this model in AD research.
THE ZEBRAFISH MODEL
The zebraﬁsh are a small, hardy freshwater ﬁsh native to India
and often kept in home aquaria. They were originally used
as a model organism for the study of vertebrate development.
However, over the last decade the zebraﬁsh model has become
increasingly employed for investigating a wide variety of human
diseases (Lieschke and Currie, 2007). The zebraﬁsh has a num-
ber of characteristics that make it a versatile animal model.
Although they lack the advanced cognitive behaviors evident in
rodent models, their transparent embryos, rapid development
ex utero and large reproductive capacity (100+ embryos per
spawning) provide obvious advantages over mammalian mod-
els. Furthermore, multiple genes can be manipulated simply
and effectively in the zebraﬁsh at physiologically relevant lev-
els (Newman et al., 2012), which cannot be currently achieved
in rodent models. While, in general, rodents more closely
model human physiology than ﬁsh, zebraﬁsh nevertheless are
vertebrates and so are more relevant to understanding human
biology than invertebrate models as Drosophila melanogaster and
Caenorhabditis elegans. Zebraﬁsh embryos are particularlymanip-
ulable due to their large size, ready availability and the ability
to exploit changes in their development for assay of particular
gene activities (Nornes et al., 2009). Thus, zebraﬁsh embryos can
often present a felicitous vertebrate system in which to exam-
ine the molecular and cellular functions of genes implicated in
AD.
The zebraﬁsh genome is extensively annotated. The zebraﬁsh
(teleost-bony ﬁsh) evolutionary lineage separated from the human
(tetrapod) lineage approximately 450 million years ago (Kumar
and Hedges, 1998). Teleosts appear to have undergone an addi-
tional round of genome duplication since their separation from
the tetrapod lineage followed by loss of many of the duplicated
genes (Catchen et al., 2011). However, in most cases, zebraﬁsh
genes can be identiﬁed that are clear orthologs of human genes.
Zebraﬁsh possess genes orthologous to the human genes that are
thought to play essential roles in AD. The psen1 (Leimer et al.,
1999) and psen2 (Groth et al., 2002) genes are orthologs of human
PSEN1 and PSEN2, respectively, while the appa and appb genes are
“co-orthologs” of human APP (Musa et al., 2001). Zebraﬁsh hold
orthologous genes for the components of the gamma-secretase
complex, PSENEN (psenen; Francis et al., 2002; Campbell et al.,
2006), NCTN (ncstn; Strausberg et al., 2002) and APH1b (aph1b;
Francis et al., 2002). While orthologs of β-secretase (BACE1 and
BACE2) have also recently been identiﬁed in zebraﬁsh: bace1
(Moussavi Nik et al., 2012) and bace2 (van Bebber et al., 2013).
The microtubule-associated protein tau (MAPT) gene in humans
encodes the tau protein and our laboratory identiﬁed co-orthologs
of this gene in zebraﬁsh, mapta, and maptb (Chen et al., 2009).
Zebraﬁsh also possess co-orthologs of APOE: apoea and apoeb
(Babin et al., 1997; Woods et al., 2005). Genes arising by duplica-
tion can have overlapping functions. This can be disadvantageous
when analyzing gene function as particular loss-of-function phe-
notypes may be obscured unless the function of both duplicate
genes is blocked. Alternatively, duplicate genes can have partially
non-overlapping functions and this can facilitate functional anal-
ysis as loss-of-function phenotypes may be restricted to particular
cells or tissues.
Zebraﬁsh are an advantageousmodel for genetic andmolecular
studies. Zebraﬁsh embryos are genetically malleable by injection
of morpholino antisense oligonucleotides, mRNA, transgenes and
more recently by genome engineering systems (reviewed inHwang
et al., 2013; Schmid and Haass, 2013; Hisano et al., 2014). These
technologies can make both subtle and drastic changes in gene
expression with the effects observed in the developing transparent
embryos. Morpholinos are designed to bind to particular sites in
transcripts from a gene of interest. Binding of a morpholino can
either blockmRNA translation (knockdown) or interferewith cor-
rect splicing of exons (e.g., Draper et al., 2001; Nornes et al., 2008;
Berger et al., 2011). Injection of sense mRNA can allow overex-
pression of a particular gene of interest. The effects of morpholino
and mRNA injection generally only persist during embryogenesis
(2–3 days post-fertilization). Transgenic zebraﬁsh can be gener-
ated using efﬁcient vectors such as the Tol2 transposase system
(Kawakami et al., 2000) to insert genes under the control of tissue
speciﬁc promoters. Conditionally expressed transgenics can also
be generated using the Cre/loxP (Hans et al., 2009) andGAL4-UAS
(Halpern et al., 2008) systems for gene function analysis at partic-
ular time points. The absence of technology available to generate
targetedmutations in the zebraﬁsh genomewas previously a disad-
vantage of the zebraﬁsh model relative to rodents. In recent times
however, zinc ﬁnger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENS) and the type II prokaryotic CRISPR
(clustered regularly interspaced short palindromic repeats)/Cas
systems have been developed for targeted modiﬁcation of gene
sequences in the zebraﬁsh genome (Hwang et al., 2013; Schmid
and Haass, 2013).
A search of the available scientiﬁc literature in the PubMed
database using the term“zebraﬁsh + alzheimer’s disease” revealed
119 publications with 98 being original research papers (23rdMay,
2014). Figure 1 displays the research areas in which these papers
have beenpublished. There is anobvious concentrationof research
on Aβ and Presenilin function in zebraﬁsh.
USING ZEBRAFISH TO INVESTIGATE GENES MUTATED IN
FAD
THE PRESENILINS
The genes implicated in FAD have been extensively studied
over the last 25 years, although our understanding of their
normal functions is still far from complete. The PSEN genes
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FIGURE 1 |Text mining analysis of the scientific literature to detect
papers on the application of Zebrafish in Alzheimer’s disease research.
The PubMed database was mined for zebraﬁsh and Alzheimer’s disease using
the search term, “zebraﬁsh+alzheimer’s disease,” by the MedScan Reader 5
tool implemented in the Pathway Studio 9 Package (Nikitin et al., 2003b;
Novichkova et al., 2003a). MedScan Reader 5 collects information and
processes undertaken data using natural language processing (NLP). The
language interprets these to logical concepts and extracts functional
relationships between proteins, small molecules, and cellular processes
(Nikitin et al., 2003b; Novichkova et al., 2003a). 119 publications were found.
Abstracts of these publications were studied and review papers were
removed such that 98 papers remained. (A) Venn diagram and (B) bar graph
showing numbers of research papers in different areas. A concentration of
research on Amyloidβ and Presenilin function is apparent.
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play important roles in development. The zebraﬁsh (as well-
characterized model for studies of developmental biology) has
been employed to investigate the normal functions of these
genes. The psen1 and psen2 genes are ubiquitously expressed
in zebraﬁsh embryos (Leimer et al., 1999; Groth et al., 2002),
implying a functional importance of these genes during devel-
opment. Injection of morpholinos to knockdown presenilin gene
expression revealed similar and dissimilar phenotypes compared
to Presenilin knockout mice (Psen1−/−). Psen1−/− mice die
during development (Shen et al., 1997). To overcome this, con-
ditional Psen1 knockout mouse models have been developed
(reviewed in van Tijn et al., 2011). Zebraﬁsh embryos injected
with a psen1 translation-blocking morpholino are viable and have
similar phenotypes (Nornes et al., 2003; Campbell et al., 2006;
Nornes et al., 2008) to Psen1−/− mice such as aberrant somite
formation and Notch signaling defects (Shen et al., 1997; Wong
et al., 1997) Interestingly, a zebraﬁsh mutant (discovered in a
TILLING screen) lacking Psen1 activity is viable (Sundvik et al.,
2013). These mutant ﬁsh have been used to study the brains
histaminergic system (Sundvik et al., 2013). This system is essen-
tial in mediating cognitive functions affected in AD. Analysis
of histamine neuron numbers in the psen1−/− zebraﬁsh brains
revealed that psen1 in zebraﬁsh is a regulator of histaminergic
neuronal development (Sundvik et al., 2013). These mutant ﬁsh
will be a valuable tool for further analysis of psen1 function in
zebraﬁsh.
Blockage of Psen2 protein translation in zebraﬁsh embryos
(Nornes et al., 2008, 2009) appears to have major effects on Notch
signaling in comparison to Psen2−/− mice which are viable and
show only a minor phenotype (Herreman et al., 1999). Further-
more, loss of Psen2 expression affects the production of dorsal
longitudinal ascending (DoLA) interneurons in the developing
spinal cordof zebraﬁsh larvae (Nornes et al., 2009). As loss of Psen1
does not affect DoLAs this observation provides an in vivo assay
for Psen2 function. This assay was used to demonstrate a func-
tional interaction between Psen1 and Psen2 in zebraﬁsh (Nornes
et al., 2009).
In the absence of technology available to analyze PSEN
FAD missense mutations in zebraﬁsh, our laboratory previously
attempted to model PSEN1 splicing mutations by injecting mor-
pholinos that target splice acceptor sites of the orthologous psen1
gene. We attempted to cause exon skipping to exclude exon 8
or 9 from zebraﬁsh psen1 transcripts to mimic the effects of the
human PSEN1 L271V and 9 mutations, respectively,. However,
instead of the (at that time) expected exon exclusion, injec-
tion of morpholinos blocking splice acceptor sites lead to the
failure of introns 7 and 8 to be correctly spliced out of tran-
scripts (Nornes et al., 2008). The inclusion of intron sequence
lead to premature truncation of the open reading frame (ORF)
after exons 6 and 7, respectively. It appeared that the aberrant
transcripts induced by morpholino injection were able to evade
nonsense-mediated decay and be translated into truncated pro-
tein molecules. Assays developed in our laboratory (discussed in
the next section) demonstrated that truncation of the zebraﬁsh
psen1 transcript ORF after exons 6 and 7 had potent dominant
negative effects on Psen1 activity and could also suppress Psen2
activity (Nornes et al., 2008). These putative truncated proteins
were subsequently expressed in embryos by injection of synthetic
mRNAs. Injection of mRNAs coding for proteins truncated after
exon 6- or 7-derived sequence had the same dominant effect on
Psen1 activity as the morpholino-induced aberrant psen1 tran-
scripts. Recently we published results where we expanded the
original study to analyze a series of psen1 ORF truncations (i.e.,
after exon 4, 5, 6, 7, 8; Newman et al., 2014). We found differ-
ential, dominant activation of Notch signaling and APP cleavage
amongst the different truncations of Psen1. Interestingly, simi-
lar effects were also observed after injection of synthetic mRNAs
encoding equivalent truncations of human PSEN1. This supports
the evolutionary conservation of function of these truncated pro-
teins. A particularly important discovery from this study was that
the activity of a form of Psen1 truncated after exon 4 sequence of
the ORF) cannot be observed in the absence of normal endoge-
nous Psen1. This implies that mutant forms of PSEN1 require
endogenous normal PSEN1 to exert their effects. A similar obser-
vation was made recently by Heilig et al. for various FAD mutant
forms of the PSEN1 protein in mouse embryo ﬁbroblasts (Heilig
et al., 2013).
OTHER COMPONENTS OF THE γ-SECRETASE COMPLEX
There has been limited functional analysis of the zebraﬁsh
genes ortholgous to the non-PRESENILIN components of the
γ-secretase complex. Blockage of translation of Psenen or Aph1b
proteins in zebraﬁsh causes phenotypes including defective somi-
togenesis and reduced neuron formation as expected for loss of
Notch signaling (that requires γ-secretase activity; Campbell et al.,
2006). Furthermore, blockage of Psenen translation leads to desta-
bilization of Psen1 protein and causes a much greater induction
of apoptosis in developing embryos than blocking translation of
Psen1, Psen2, or Aph1b (Campbell et al., 2006). Simultaneous
inhibition of p53 translation was able to block the induction of
apoptosis (Campbell et al., 2006).
THE AMYLOID-BETA PRECURSOR PROTEIN
The zebraﬁshAPP “co-orthologs,”appa and appb have widespread
and overlapping expression frommid-gastrulation in the develop-
ing embryo (Musa et al., 2001). At 24hpf both genes are expressed
in the developing forebrain and other tissues with only appb
expressed in the spinal cord (Musa et al., 2001). In a zebraﬁsh
study by Lee and Cole a section of appb regulatory sequence was
fused to GFP (Lee and Cole, 2007). Dissimilar to other expression
studies, they observed expression of appb in the developing vascu-
lature. More recently, Liao et al. (2012) isolated transposon gene
trap integrations that contained RFP in the appa gene and in the
closely related amyloid beta precursor-like protein 2 gene (aplp2).
The gene traps caused fusions to RFP of the extracellular domains
of both of the encoded proteins. The fusion proteins of these
genes were accumulated in the vasculature. However, they could
not detect the transcripts of these genes in the endothelial cells
of the vasculature. Instead, transcripts were detected in neuronal
cells. This suggests that these proteins are synthesized in neuronal
cells and then accumulate in the vasculature.
Translation blocking morpholinos have also been employed to
investigate the function of the Appa and Appb proteins (Joshi
et al., 2009). Inhibition of Appa had little effect on the developing
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embryo while Appb translation inhibition resulted in defective
convergent extension cellular movements and a reduced body
length. These defects could be rescued by injecting Appb deﬁ-
cient embryos with mRNA coding for human APP. The rescue
by human APP was more effective than injection of an mRNA
encoding a human APP FAD mutant (the APP Swedish dou-
ble mutation K595N and M596L). Loss of Appb activity has
also been shown to cause defective neural development (Song
and Pimplikar, 2012) including defective axonal out-growth pat-
terning and synapse formation (Abramsson et al., 2013). In the
study by Song and Pimplikar, only full-length human APP
but not truncated forms could rescue the neuronal defects,
revealing that both intracellular and extracellular domains of
human APP are required for normal function (Song and Pim-
plikar, 2012). These studies demonstrate that zebraﬁsh embryos
can be exploited for the analysis of different mutant forms of
human APP.
AMYLOID-BETA FUNCTION AND TOXICITY STUDIES IN ZEBRAFISH
Although Aβ was discovered over 25 years ago (Goate and Hardy,
2012) and many studies have examined its claimed toxicity, the
non-pathological functions of the Aβ peptide are still poorly
understood. A study by Cameron et al. (2012) demonstrated that
high levels of Aβ can increase cerebrovascular branching in the
developing zebraﬁsh hindbrain. They then completed a follow
up study to determine whether lowering Aβ levels would have
the opposite effect (Luna et al., 2013). From 2 days post fertil-
ization (dpf) APP-deﬁcient (by morpholino injection) and Aβ
deﬁcient (endogenous Aβ production blocked using a β-secretase
inhibitor) larvae presented with cerebrovascular defects. Interest-
ingly, these defects could be rescued by treating the embryos with
the human Aβ-42 peptide but not the shorter cleavage product of
APP named p3 (that arises from cleavage of APP by α-secretase
and γ-secretase). These results suggest that Aβ may play a role
in maintaining normal cerebrovascular function. This interesting
ﬁnding using the zebraﬁsh model provided further evidence that
caution should be taken when treating AD with drugs designed
to inhibit Aβ production such as BSIs and γ-secretase inhibitors
(GSIs).
As mentioned above the amyloid hypothesis of AD proposes
that aggregations of Aβ peptides are toxic. Therefore, there has
been a considerable effort put towards developing and discover-
ing Aβ-lowering compounds to counter the toxicity. Inhibition
of β-secretase, also known as beta-site APP cleaving enzyme
(BACE1), is of prime interest for the development of amyloid-
lowering drugs. BACE1 has become an attractive target for drug
development as, in comparison to the lethality observed in Psen1
null mice, Bace1 knock-out mice are viable (Roberds et al., 2001;
Luo et al., 2003) and have subtle phenotypes (Harrison et al.,
2003; Willem et al., 2006). Furthermore no phenotypes have been
reported for knockout of the Bace1 homolog, Bace2 and dele-
tion of Bace2 in mice did alter Aβ generation (Dominguez et al.,
2005). Recently, bace1 and bace2 loss-of-function mutations have
been introduced into the zebraﬁsh genome by genome editing
using ZFNs (van Bebber et al., 2013). bace1 mutants had an
increased number of mechanosensory neuromasts and, similar
to observations in the mouse, Bace1 knockout caused a decrease
in myelination. bace2 mutants had a distinct melanocyte migra-
tion phenotype that was not observed in the bace1 mutants.
There was no effect on myelination or neuromasts in the bace2
mutants. The phenotypes observed in the single mutants were not
enhanced further in the Bace1/2 double knockout. Together the
data from this study suggests that, in zebraﬁsh, Bace1 and Bace2,
have distinct non-redundant physiological functions. These spe-
ciﬁc phenotypes observed in zebraﬁsh bace1 and bace2 mutants
haveprovided important informationonBACE1andBACE2 func-
tion and support that zebraﬁsh can be a useful in vivo system for
determining, e.g., whether BACE1 inhibitors also inhibit BACE2
function and vice versa. In vivo evaluation of BACE inhibitors
is integral for establishing these drugs as a therapeutic option
for AD.
The zebraﬁsh is an excellent system for the screening of chem-
ical libraries. Embryos and larvae placed into microtiter plates
can be treated with various chemicals in their aqueous support
medium. This strategy can be employed to reveal therapeutic com-
pounds for various disease states modeled in the ﬁsh. The only
published study that has generated a transgenic Aβ toxicity model
in zebraﬁsh involved fusing the humanAβ-42 sequence to the pro-
moter of themitfa (nacre) gene (Newman et al., 2010). This would
drive expression of human Aβ-42 speciﬁcally in the melanin-
containing pigment cells (melanocytes) of the zebraﬁsh in the
hope that it would produce an easily identiﬁable disrupted pig-
mentation pattern phenotype without being lethal to the zebraﬁsh
larvae. A disrupted pattern did become evident in the adult ﬁsh.
However, unfortunately it only became apparent after 16 months
which is too late for drug screening and was too late for breeding
the old, infertile ﬁsh. Aβ toxicity can also be analyzed in zebraﬁsh
simply by exposing embryos to amyloid-beta in their support-
ive aqueous environment. Treatment of embryos with 2.5 μM
Aβ-40 caused defective development including that of the vascu-
lature and also accelerated cell senescence (Donnini et al., 2010).
This system could be expanded to test Aβ-42 (more aggregative
form) and also to ﬁnd compounds that ameliorate these observed
defects.
γ-secretase inhibitors (GSIs) have been investigated as a thera-
peutic option to inhibit the production of Aβ peptides. However,
the use of GSIs comes with the potential side affects of also affect-
ing Notch signaling. Testing the toxicity of GSIs on zebraﬁsh has
revealed important information on how Notch related pathways
are adversely affected by GSIs (Yang et al., 2010).
ASSAYS FOR AD-RELEVANT CELLULAR PATHWAYS AND
PROCESSES IN ZEBRAFISH
γ-SECRETASE ACTIVITY ASSAYS
There are a number of cellular pathways and processes that are
aberrant in AD. The zebraﬁsh are a useful system for investigating
molecular events such as γ-secreatse activity and autophagy that
have been implicated in AD pathogenesis.
There are over 70 proteins that are known to be substrates
of γ-secreatse activity (Lleo and Saura, 2011). In zebraﬁsh,
γ-secretase activity was initially analyzed by observing changes in
the expression of genes known to be downstream targets of Notch
signaling such as hairy-related 6 (Bernardos et al., 2005; Campbell
et al., 2006; Arslanova et al., 2010) and neurogenin (Campbell et al.,
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2006). However, gene expression can be under different transcrip-
tional control in different regions of the embryo (Campbell et al.,
2006; Arslanova et al., 2010). Therefore, using whole embryos in
quantitative PCR analysis is not informative to assess changes in
gene expression in response to various factors. To overcome this,
changes in gene expression in a particular region of the embryos
havebeen assessedbywhole-mount in situ transcript hybridization
(Campbell et al., 2006; Nornes et al., 2008; Arslanova et al., 2010).
However, this is not normally used as a quantitative technique
since many variables can inﬂuence the strength of the staining
signal such as ﬁxation conditions and incubation times. Conse-
quently, use of this technique to assay relative differences in Notch
signals under various treatments requires stringent controls.
Recently, the ﬁrst assay to assess directly γ-secretase cleav-
age activity was developed by Wilson and Lardelli (2013).
α- and β-secretase cleavage of Appa provide substrates for sub-
sequent γ-secretase cleavage. Unfortunately these cleaved forms
of Appa cannot be detected in zebraﬁsh embryos prior to 48 hpf
which currently makes monitoring endogenous Appa cleavage in
manipulated zebraﬁsh embryos difﬁcult. Therefore, a fragment
of Appa equivalent to the membrane-embedded remnant of APP
following β-secretase cleavage was fused to GFP and expressed
transiently in zebraﬁsh embryos by the use of Tol2 vector trans-
genesis system. This construct is co-expressed with a set ratio
of free GFP (for signal normalization). Western immunoblot-
ting is then used to assess the ratio of the Appa:GFP substrate
to free GFP (the γ-secretase cleavage product itself is too unsta-
ble to be observed). Once an Appa:GFP/ free GFP ratio is
determined for a protein sample from a pool of manipulated
embryos (e.g., drug treatment, morpholino or mRNA injec-
tion) it can then be compared to control embryos to determine
how that particular manipulation is affecting γ-secretase cleavage
activity.
ASSAYING PROTEIN DEGRADATION PATHWAYS IN ZEBRAFISH
Excess or aberrant cellular proteins can be degraded by the
ubiquitin-proteasome system (UPS). Since protein aggregation is
implicated in many neurodegenerative diseases (Ross and Poirier,
2004) it is unsurprising that problems with UPS function have
been implicated in neurodegenerative disease such as AD (West
et al., 1994; Nikitin et al., 2003a; Novichkova et al., 2003b) and
Parkinson’s disease (Olanow and McNaught, 2006). Zebraﬁsh
have been used to investigate UPS function in Parkinson’s dis-
ease (Regeur et al., 1994); however, no analyses in zebraﬁsh have
yet examined the UPS with respect to AD.
Autophagy is an important mechanism required for the
degradation of dysfunctional and unwanted cellular components
(including incorrectly folded and aggregated proteins) through the
actions of lysosomes. Indeed, autophagy has been identiﬁed as a
pathway for the degradation of accumulated Aβ peptides (Nilsson
et al., 2013). Recently, the Presenilin proteins were suggested to
have a major role in autophagy with FAD mutations in human
PSEN1 inhibiting this function (Lee et al., 2010). These authors
presented evidence showing that PSEN1 acts as a chaperone in
the ER for a transmembrane protein required for acidiﬁcation
of the lysosomes, the v-ATPase V0a1 subunit [Lee et al., 2010;
however, other reports have disputed this ﬁnding (Coen et al.,
2012; Zhang et al., 2012)]. They also demonstrated that this
function of PSEN1 is dependent on the full-length PSEN1 holo-
protein rather than the endoproteolysed form that is active in
the γ-secretase complex. Furthermore, a γ-secretase inhibitor and
loss of another γ-secretase complex component (NCT) had no
effect on autophagy (Lee et al., 2010) suggesting that this func-
tion of PSEN1 is independent from its function in γ-secretase
complexes.
Autophagy can be analyzed in zebraﬁsh by observing induction
of the LC3-II protein by western immunoblotting using a human
antibody against LC3 that cross-reacts with zebraﬁsh Lc3 (He et al.,
2009; He and Klionsky, 2010). Transgenic zebraﬁsh have also been
developed that express GFP fused to Lc3 (He et al., 2009). As Prese-
nilin protein expression can easily be manipulated in the zebraﬁsh
these autophagy assay are a useful tool for further investigation of
the involvement of the Presenilins in autophagy.
USING THE ZEBRAFISH TO INVESTIGATE OTHER ASPECTS OF
ALZHEIMER’S DISEASE ETIOLOGY
ANALYSIS OF HYPOXIA IN THE ZEBRAFISH
There is accumulating evidence suggesting that hypoxia is an
important initiating factor in the pathogenesis of AD. Under
hypoxic conditions the electron transport chain in the mito-
chondria increases free radical production that leads to increased
oxidative stress (Bell et al., 2007). Biomarkers of hypoxia can dif-
ferentiate between people with mild cognitive impairment that
progress to AD and those who do not (Oresic et al., 2011). The
risk factors for cardiovascular disease and AD are similar (Kotze
and van Rensburg, 2012) and it is anticipated that vasculature
problems would affect oxygenation of the brain. Interestingly, Aβ
levels in serum have been shown to be elevated after cardiac arrest
(Zetterberg et al., 2011).
Zebraﬁsh are an advantageous system for analysis of the effects
of hypoxia on various biological functions. Zebraﬁsh embryos and
adults can be exposed to real hypoxia by depleting their water envi-
ronment of oxygen or to chemical mimicry of hypoxia through,
e.g., sodium azide treatment (Moussavi Nik et al., 2011). Similarly
to what is observed in humans (Lukiw et al., 2001; Pluta, 2005;
De Gasperi et al., 2010; Zhang and Le, 2010), hypoxia upregu-
lates psen1, psen2, appa, appb, and bace1 in zebraﬁsh adult brain
and larvae (Moussavi Nik et al., 2012). This suggests that Aβ is
produced as a protective response to hypoxia in both human and
zebraﬁsh cells – a response conserved over 450 Mya of evolu-
tionary time. Note, however, that while all the enzymes required
to cleave Aβ from Appa and/or Appb are present in zebraﬁsh,
the existence of Aβ itself has not yet been directly demonstrated
(e.g., through immunoblotting or mass spectrometry). The study
by Moussavi Nik et al. (2012) also demonstrated that, unlike in
mammals, F2-isoprostanes are not a good marker of oxidative
stress in zebraﬁsh and that the upregulation of catalase gene
expression can be a better alternative marker for demonstra-
tion of oxidative stress in zebraﬁsh (Jin et al., 2011; Tseng et al.,
2013).
APOE
The APOE ε4 allele has been identiﬁed has the main genetic risk
factor for SAD. APOE is important for clearance of amyloid-beta
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from the brain (Huang and Mucke, 2012), while the AD risk-
associated ε4 allele has been shown to impair the clearance of
Aβ (Deane et al., 2008) and, more recently, to affect the integrity
of the blood–brain barrier (Bell et al., 2012). There has been lit-
tle research investigating APOE function in zebraﬁsh. Expression
studies of apoea (Raymond et al., 2006) and apoeb (Pujic et al.,
2006) revealed expression in the developing retina and yolk syncy-
tial layer. Furthermore, apoeb has also been observed in microglial
cells (Veth et al., 2011), developing ﬁns and epidermis (Monnot
et al., 1999; Tingaud-Sequeira et al., 2006), regenerating ﬁn tis-
sue (Monnot et al., 1999), macrophages (Lien et al., 2006), liver,
intestine, and ovary (Levi et al., 2012).
MAPT
The MAPT is the main component of the NFTs found in AD
brains. Various dysfunctions of the tau protein are found in
other neurodegenerative disorders such as frontotemporal demen-
tia (FTD), corticobasal degeneration and progressive supranuclear
palsy (Pittman et al., 2006). Diseases with tau-like pathology are
collectively termed “tauopathies.” A review by Bai and Burton
(2011) discussed how the zebraﬁsh has been used to investigate
these diseases. AnumberofMAPTprotein isoforms exist as a result
of alternative splicing of MAPT transcripts. These isoforms can
be classiﬁed into two groups, 3R or 4R, depending on the number
of tubulin-binding motifs. It appears that an overall one-to-one
ratio of 3R to 4R transcripts is required for normal functioning of
the MAPT protein in the brain (Goedert and Spillantini, 2006). In
most tauopathies this ratio is found to be changed (Goedert and
Spillantini, 2006) and altered splicing of MAPT is also suggested
to occur in AD brains (Conrad et al., 2007).
Transgenic zebraﬁsh expressing human MAPT were gener-
ated and investigated prior to identiﬁcation of the zebraﬁsh
ortholog(s) of MAPT. In these studies human MAPT was specif-
ically expressed in zebraﬁsh CNS neurons (Bai et al., 2007; Paquet
et al., 2009). Bai et al. used the promoter of the enolase 2 gene
to drive the expression of MAPT 4R in zebraﬁsh neurons at
approximately eightfold higher levels than what is observed in
human brain. This resulted in accumulations of tau protein
(resembling NFTs) in the zebraﬁsh brain. In the study by Paquet
et al., the HuC promoter was employed to drive expression of
a Gal4:VP16 fusion protein in neurons. This protein was then
bound to UAS sites in a bidirectional promoter transcribing the
DsRed ﬂuorescent marker protein gene and a mutant form of
human MAPT associated with FTD, TAU-P301L. The transgenic
zebraﬁsh larvae showed biochemical changes consistentwith those
observed in human tauopathies. However, it should be noted
that no comparisons of phenotype were made between the non-
mutant and mutant forms of human MAPT in the zebraﬁsh.
Furthermore, the expression levels of the transgenes relative
to the endogenous zebraﬁsh mapt genes were not assessed in
these studies. Despite these limitations these transgenic zebraﬁsh
models provide a useful system to investigate whether chemi-
cal inhibitors can modulate the observed tauopathy-associated
changes.
The zebraﬁsh “co-orthologs”of the humanMAPT gene,mapta
and maptb have similar but not completely overlapping patterns
of expression in developing embryos (Chen et al., 2009). They are
both predominantly expressed in the developing CNS while only
maptb has strong expression in the trigeminal ganglion and dorsal
sensory neurons of the spinal cord. Mapta is spliced into 4R–
6R isoforms while maptb is spliced mainly into 3R isoforms. This
expression is in contrast tomouseMapt which is mainly expressed
as 3R in the brain (and hence may not be a good model of MAPT
function for human pathologies). Manipulation of the expression
of the zebraﬁsh mapt isoforms may therefore be advantageous for
understanding the function of 3R and 4R MAPT and the role(s)
the 3R:4R ratio plays in pathogenesis.
THE FUTURE FOR MODELING ALZHEIMER’S DISEASE IN
ZEBRAFISH
The zebraﬁsh is rapidly emerging as an attractive model for AD
research. They are an ideal model for drug testing prior to clinical
testing in rodents. However, there are still aspects of this model
that require better understanding. For the zebraﬁsh system to be
used tomodel aspects of ADpathobiologyweneed to better under-
stand zebraﬁsh brain structure and function and also gain a deeper
understanding of adult zebraﬁsh brain physiology. Work so far
has revealed that the zebraﬁsh brain does have a reasonable level
of conservation of basic structure when compared to mammals
as well as similar neuroanatomical and neurochemical pathways
to those that play roles in human disease (reviewed in Santana
et al., 2012). We have revealed various aspects of presenilin gene
biology using the zebraﬁsh that would otherwise be difﬁcult to
observe/analyze in other models. However, to analyze effectively
future transgenic and mutant zebraﬁsh models of AD we need
to strengthen our understanding of the functions in zebraﬁsh of
some of the orthologs of the key genes implicated in human AD
pathogenesis such as MAPT and APOE.
Whether the zebraﬁsh can be employed to model a late-onset
disease like AD is debatable since zebraﬁsh have a profound
capacity for regeneration and this must impact on the devel-
opment of neurodegenerative phenotypes. Neurogenesis in the
adult zebraﬁsh brain is much more abundant than is observed in
mammals (Kizil et al., 2012) consequently making analysis of neu-
ronal loss difﬁcult. Despite these limitations the recent availability
and feasibility of using genome editing technologies presents an
exciting opportunity to develop zebraﬁsh genetic models of neu-
rodegenerative diseases such as AD. ZFNs, TALENs and CRISP/Rs
have been validated for use in the zebraﬁsh [reviewed by Hwang
et al., 2013; Schmid and Haass, 2013) and it is inevitable that FAD
mutations will be introduced into zebraﬁsh FAD gene orthologs.
Animal models are a useful tool in investigating the causes and
pathologies of human diseases. Obviously such models can never
reﬂect the complete pathology that is observed in human cases.
The complexity of the human brain makes AD a particularly dif-
ﬁcult disease to model in animals. However, by using a number
of different models including the zebraﬁsh, we can exploit the
unique characteristics of each to unravel the molecular basis of
this disease.
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